2009 Biopharma Deals Of The Year: Roche/Genentech, Movetis' IPO, Elan/J&J
Which pharmaceutical and biotech deal-making and financing developments of the past year are the most surprising, creative or precedent-setting
You may also be interested in...
Notable biotech financings in November also include ThromboGenics, NicOx: 4SC AG, and Fate Therapeutics.
J&J gets to build its fledgling Alzheimer's program, while Elan gets cash to strengthen its balance sheet, plus a new minority shareholder and strong global partner.
The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.